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ABSTRACT 
The manuscript describes validated absorbance correction method for the estimation of nebivolol and amlodipine besylate in combined 
dosage  form.  Absorbance  correction  method  was  based  on  property  of  additivity  of  absorbances.  The  two  wavelengths  on amlodipine 
besylate curve were found out where it showed same absorbance, which were 262 and 332.5 nm. At 332.5 nm, amlodipine besylate showed 
some absorbance while nebivolol showed zero absorbance. Both the drugs gave absorbance at 262 nm. The method involved solving of an 
equation based on measurement of absorbance at two wavelengths 262 and 332.5 nm. The determinations were made at 262 for nebivolol 
and  amlodipine  besylate  and  332.5  nm  for  amlodipine  besylate  over  the  concentration  range  of  10-70  µg/ml  for  both  nebivolol  and 
amlodipine besylate with mean recovery of 99.7 ± 0.15 and 99.4 ± 0.18 % for nebivolol and amlodipine besylate, respectively by absorbance 
correction method. This method was found to be simple, sensitive, accurate, precise, reproducible, and economical and can be applicable for 
the simultaneous determination of nebivolol and amlodipine besylate in combined dosage form. 
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INTRODUCTION 
Nebivolol  (NEBI)  is  an  antihypertensive  drug  and 
chemically  is,  α,α
1–(imino  bis  (methylene))  bis  (6-
fluoro-3,  4-dihydro-2  H  -1-benzopyran-2-methanol), 
which  is  a  selective  β1  -receptor  antagonist  without 
partial  agonist  activity
1.  Literature  survey  reveals 
HPLC
2-3,  HPTLC
4,  LC-MS
5  and  spectrophotometry
6 
methods for estimation of NEBI in single dosage form. 
Amlodipine besylate (AMLO) is a long-acting calcium 
channel  blocker  used  as  an  anti-hypertensive  in  the 
treatment  of  angina  and  chemically  is  (RS)-3-ethyl-5-
methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-
1,4-dihydro-6-methyl-3,5  pyridinedicarboxylate 
benzenesulfonate;  2-[(2-Aminoethoxy)  methyl]-4-(2-
Chloro-  phenyl)-3-Ethoxycarbonyl-5-Methoxycarbonyl- 
6-Methyl-1,  4-Dihydropyridine
1.  It  is  official  in  IP.  IP 
describe  HPLC
7  method  for  its  estimation  Literature 
survey  also  reveals  spectrophotometry
8,  HPLC
9, 
spectrofluorimetry
10,  differential-pulse  voltammetry
11, 
LC
12,  LC/MS/MS
13  and  HPTLC
14  methods  for 
estimation of AMLO in pharmaceutical formulations and 
in biological fluids. This combination is not official in 
any pharmacopoeia hence no official method is available 
for  estimation  of  these  two  drugs  in  combined  dosage 
form.  Literature  survey  reveals  HPTLC
15-16  and 
spectrophotometric
17 method for simultaneous estimation 
of  NEBI  and  AMLO  in  combined  dosage  form.  The 
present manuscript describes alternative simple, sensitive, 
accurate,  precise,  reproducible,  and  economical 
absorbance  correction  method  for  simultaneous 
estimation  of  NEBI  and  AMLO  in  combined  dosage 
form.  
MATERIAL AND METHODS 
Apparatus 
Shimadzu  (UV-1700)  double  beam  UV-Visible 
spectrophotometer  attached  with  computer  operated 
software  UV  probe  with  spectral  width  of  2  nm, 
wavelength accuracy of 0.5 nm and pair of 1 cm matched 
quartz  cells,  Sartorius  CP224S  analytical  balance 
(Gottingen, Germany), ultra sonic cleaner (Frontline FS 
4,  Mumbai,  India)  and  corning  volumetric  flasks  were 
used during the study. 
Reagents and Materials 
Pharmaceutical grade of NEBI and AMLO was kindly 
supplied as a gift samples from Torrent Pharmaceutical 
Ltd,  Gujarat  (India)  with  99.97%  purity.  The 
pharmaceutical formulations containing 5 mg NEBI and 
5  mg  AMLO  of  brand  A  and  brand  B  were  procured Patel Satish A et al. IRJP 2 (8) 2011 92-95 
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from  the  local  pharmacy.  Methanol  (AR  grade)  were 
purchased from Finar Chemicals Ltd, Ahmedabad India, 
and nylon 0.45 µm – 47 mm membranes filter (Gelman 
Laboratory, Mumbai, India) were used in the study. 
Methodology 
Absorbance spectrum of pure AMLO was scanned in the 
spectrum  basic  mode.  Using  the  cursor  function,  the 
absorbance corresponding to 332.5 nm (wavelength λ1, 
the wavelength of minimum absorbance for AMLO) was 
noted  from  spectrum.  Then  the  cursor  function  was 
moved along with peak curve until the absorbance equal 
to  that  of  absorbance  at  332.5  nm  was  found.  The 
wavelength  obtain  corresponding  to  this  absorbance 
value  was  262  nm  (λ2).  The  absorbance  of  various 
dilutions of AMLO in methanol was measured at 332.5 
nm.  Absorbance  spectrum  of  pure  NEBI  was  also 
scanned in the spectrum basic mode. NEBI showed some 
absorbance value at 262.0 nm (λ2) while it dose not show 
any absorbance value at 332.5 nm. The absorbance value 
at  332.5  nm  is  due  to  AMLO  only  in  the  combined 
mixture  of  both  drugs.  Wavelength  λ1 (332.5  nm)  was 
selected for the measurement of AMLO. 
Preparation of NEBI and AMLO standard stock 
solutions 
A  mixed  stock  solution  of  NEBI  ((100  µg/ml)  and 
AMLO  (100  µg/ml)  was  prepared  by  accurately 
weighing  NEBI  (100  mg)  and  AMLO  (100  mg), 
dissolving  in  methanol  and  diluted  to  100  ml  with 
methanol in the same volumetric flask. 
Preparation of sample solution   
Twenty  tablets  were  weighed  and  powdered.  The 
quantity of the powder equivalent to 5 mg of NEBI and 
10 mg of AMLO was transferred to a 50 ml volumetric 
flask.  The  content  was  mixed  with  methanol  (30  ml), 
sonicated for 20 min. to dissolve the drug as completely 
as  possible.  The  solution  was  then  filtered  through  a 
nylon  0.45  µm  membrane  filter.  The  volume  was 
adjusted up to the mark with methanol. An aliquot of this 
solution (3.5 ml) was transferred in to a 10 ml volumetric 
flask and the volume was adjusted up to the mark with 
methanol. 
Method Validation 
The  method  was  validated  according  to  the  ICH 
guidelines
18. 
Calibration curve (linearity) 
Calibration  curves  were  plotted  over  a  concentration 
range of 10-70 µg/ml for NEBI and AMLO. Accurately 
measured mixed standard working solutions of NEBI and 
AMLO  (1.0,  2.0,  3.0,  4.0,  5.0,  6.0,  and  7.0  ml)  were 
transferred to a series of 10 ml of volumetric flasks and 
diluted to the mark with methanol and absorbances were 
measured at 332.5 nm and 262 nm for both the drugs. 
The  calibration  curves  were  constructed  by  plotting 
absorbance at 332.5 nm versus concentrations for AMLO 
and  absorbance  difference  (A262  -  A332.5)  versus 
concentration for NEBI.   
Accuracy (% Recovery) 
The  accuracy  of  the  methods  was  determined  by 
calculating  recoveries  of  NEBI  and  AMLO  by  the 
standard addition  method. Known amounts of standard 
solutions of NEBI and AMLO (15, 22.5, 30 µg/ml for 
both drugs) were added to prequantified sample solutions 
of tablet dosage form. The amounts of NEBI and AMLO 
were estimated by applying obtained values (n = 6) to the 
regression equation of the calibration curve. 
Method Precision (% Repeatability) 
The  precision  of  the  instruments  was  checked  by 
repeatedly injecting (n = 6) standard solutions NEBI and 
AMLO (40 µg/ml) without changing the parameter for 
the absorbance correction method.  
Intermediate Precision (Reproducibility) 
The  intraday  and  interday  precisions  of  the  proposed 
methods  were  determined  by  estimating  the 
corresponding responses 3 times on the same day and on 
3 different days over a period of one week for 3 different 
concentration of standard solutions of NEBI and AMLO 
(20,  40,  and  60  µg/ml).  The  results  were  reported  in 
terms of relative standard deviation (% RSD). 
Limit of Detection and Limit of Quantification   
The  limit  of  detection  (LOD)  and  the  limit  of 
quantification  (LOQ)  of  the  drug  were  derived  by 
calculating  the  signal-to-noise  ratio  (S/N,  i.e.,  3.3  for 
LOD and 10 for LOQ) using the following equations as 
per  International  Conference  on  Harmonization  (ICH) 
guidelines
18. 
LOD = 3.3 × σ/S 
LOQ = 10 × σ/S 
Where σ = the standard deviation of the response and S = 
Slope of calibration curve. 
Analysis NEBI and AMLO in combined dosage forms 
Pharmaceutical  formulation  of  NEBI  and  AMLO  was 
purchased  from  local  pharmacy.  The  responses  of 
formulations were measured at 332.5 nm and 262 nm for 
AMLO and NEBI, respectively by absorbance correction 
method as described above. The amounts of NEBI and 
AMLO present in sample solution were determined by 
fitting  the  responses  into  the  regression  equation  for 
NEBI and AMLO in the method. 
RESULTS AND DISCUSSION 
Absorbance correction method 
The utility of dual wavelength data processing program 
is  its  ability  to  calculate  unknown  concentration  of 
component  of  interest  in  a  mixture  containing  an 
interfering component. For elimination of the effects of Patel Satish A et al. IRJP 2 (8) 2011 92-95 
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an interfering component, two specific wavelengths are 
chosen.  
1. First wavelength λ1 at which minimum absorbance of 
AMLO was observed and there was no interference of 
NEBI at this wavelength (332.5 nm).  
2. Second wavelength λ2 was the wavelengths at which 
the absorbance of AMLO was same as at λ1,   and also 
NEBI  was  also  give  some  absorbance  at  this 
wavelength (262.0 nm). .  
In this proposed method the absorbance of NEBI alone in 
a  mixture  of  NEBI  and  AMLO  was  determined  using 
dual wavelength data processing program. To remove the 
interference  of  AMLO  to  the  absorbance  at  262.0  nm 
(λ2), the wavelength of minimum absorbance for AMLO, 
another  wavelength  332.5  nm  (λ1)  was  found  out  at 
which  the  absorbance  of  NEBI  was  zero.  This  was 
confirmed  by  measuring  the  absorbance  of  various 
dilution of AMLO in methanol at 262.0 nm and 332.5 
nm. The absorbance at these two wavelengths was found 
to  be  equal.  These  two  selected  wavelengths  were 
employed to determine the concentration of NEBI from 
the  mixture  of  NEBI  and  AMLO  (Figure  1).  The 
difference in absorbance at these two wavelengths (A262.0 
– A332.5) cancels out the contribution of absorbance of 
AMLO in mixture. 
Validation data of the proposed methods 
Linearity  -  Linear  correlation  was  obtained  between 
absorbance and concentration of NEBI and AMLO in the 
range  of  10-70  µg/ml.  The  linearity  of  the  calibration 
curves  was  validated  by  the  high  value  of  correlation 
coefficients of regression (Table 1).  
Accuracy - The recovery experiments were carried out 
by  the  standard  addition  method.  The  mean  recovery 
obtained was 99.7 ± 0.15 % and 99.4 ± 0.19 % for NEBI 
and  AMLO,  respectively  (Table  1).  The  high  values 
indicate that the method is accurate.  
Method precision - The % RSD values for NEBI and 
AMLO were found to be 1.13 and 0.49 (Table 1). The 
low  values  of  RSD  indicate  the  proposed  method  is 
repeatable.  
Intermediate  precision  -  The  low  RSD  values  of 
interday  (0.23-1.13  %  and  0.73-1.84  %)  and  intraday 
(0.53-2.24 % and 0.23-1.99%) variations for NEBI and 
AMLO, respectively reveal that the proposed method is 
precise (Table 1). 
LOD  and  LOQ  -  LOD  for  NEBI  and  AMLO  were 
found  to  be  0.43  µg/ml  and  1.09  µg/ml,  respectively. 
LOQ for NEBI and AMLO were found to be 1.3 µg/ml 
and 3.3 µg/ml, respectively (Table 1). These data show 
that  the  method  is  sensitive  for  the  determination  of 
NEBI and AMLO. 
 
Assay of the pharmaceutical formulation  
The  proposed  validated  methods  were  successfully 
applied to determine NEBI and AMLO in their combined 
dosage form (brand A and B). The results obtained for 
NEBI  and  AMLO  were  comparable  with  the 
corresponding labelled amounts (Table 2).  
CONCLUSION 
The results of the analysis of pharmaceutical formulation 
by  the  proposed  method  are  highly  reproducible  and 
reliable and are in good agreement with the label claim 
of  the  drug.  The  additives  usually  present  in  the 
pharmaceutical formulations of the assayed samples did 
not  interfere  with  determination  of  NEBI  and  AMLO. 
The methods can be routinty used for the analysis of the 
NEBI and AMLO in combined dosage form.   
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TABLE 1: REGRESSION ANALYSIS DATA AND SUMMARY OF 
VALIDATION PARAMETERS FOR THE PROPOSED ABSORBANCE 
CORRECTION METHOD 
 
Parameters  Absorbance correction 
method 
NEBI  AMLO 
Concentration range (µg/ml)  10-70  10-70 
Slope  0.0061  0.0029 
Intercept  0.005467  0.002867 
Correlation coefficient (r
2)  0.9952  0.9969 
LOD
a (µg/ml)  0.43  1.3 
LOQ
b (µg/ml)  1.31  3.31 
Accuracy (% recovery, n = 6)  99.7 ± 
0.154 
99.36 ± 
0.186 
Repeatability (% RSD
c, n = 6)  1.13  0.49 
Precision (%RSD)     
Interday (n = 6)  0.23-1.13  0.73-1.84 
Intraday (n = 6)  0.53-2.24  0.23-1.99 
 
aLOD = limit of detection   
bLOQ = limit of quantification   
c% RSD = percent 
relative standard deviation 
 
TABLE 2: ASSAY RESULTS FOR THE TABLET DOSAGE FORM 
 
Tablets  Absorbance correction method 
NEBI± S. D.
a 
(n
b = 6) 
AMLO ± S. D.
a 
(n
b = 6) 
Brand A  99.80 ± 1.21  99.89 ± 1.75 
Brand B  99.70 ± 0.72  98.50 ± 1.00 
 
aS. D. = standard deviation 
bn = number of determinations 
 
 
 
Figure 1: Overlain spectra of standard NEBI and AMLO in methanol 
 
 
 
Source of support: Nil, Conflict of interest: None Declared 
 